» Articles » PMID: 34807276

[Detection of BRAF V600E Mutation in Metastatic Colorectal Carcinoma : A QuIP Round Robin Test]

Overview
Journal Pathologe
Specialty Pathology
Date 2021 Nov 22
PMID 34807276
Authors
Affiliations
Soon will be listed here.
Abstract

Round robin testing is an important instrument for quality assurance. Increasingly, this also applies to the results of molecular diagnostics in pathology, which directly influence therapy decisions in precision oncology. In metastatic colorectal carcinoma (mCRC), the focus has been on detecting KRAS and NRAS mutations, whose absence allows therapy with EGFR blocking antibodies. Recently, BRAF has been added as another predictive marker, since mCRC patients with BRAF V600E mutation benefit significantly from treatment with encorafenib (a BRAF inhibitor) in combination with cetuximab (anti-EGFR antibody) after systemic therapy. Due to the approval of this treatment in 2020, it is a pre-requisite that BRAF V600E mutation detection in diagnostic pathologies is reliably performed. Therefore, this round robin test with BRAF V600E testing either by immunohistochemistry or molecular methods was performed. The round robin test results demonstrate that molecular BRAF V600E detection is currently clearly superior to immunohistochemical detection.

References
1.
Oikonomou E, Makrodouli E, Evagelidou M, Joyce T, Probert L, Pintzas A . BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia. 2009; 11(11):1116-31. PMC: 2767214. DOI: 10.1593/neo.09514. View

2.
Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

3.
Barras D, Missiaglia E, Wirapati P, Sieber O, Jorissen R, Love C . BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clin Cancer Res. 2016; 23(1):104-115. DOI: 10.1158/1078-0432.CCR-16-0140. View

4.
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T . Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. N Engl J Med. 2019; 381(17):1632-1643. DOI: 10.1056/NEJMoa1908075. View

5.
Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View